Thomas Hatschek
Overview
Explore the profile of Thomas Hatschek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1741
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kouvaraki M, Zerdes I, Sifakis E, Sarafidis M, Matikas A, Tzoras E, et al.
Int J Cancer
. 2024 Dec;
156(8):1621-1633.
PMID: 39729390
Sterile alpha motif and HD domain-containing protein 1 (SAMHD1) is a dNTP hydrolase important for intracellular dNTP homeostasis and serves as tumor suppressor and modulator of antimetabolite efficacy in cancer,...
2.
Wang K, Zerdes I, Johansson H, Sarhan D, Sun Y, Kanellis D, et al.
Nat Commun
. 2024 May;
15(1):3837.
PMID: 38714665
Although metabolic reprogramming within tumor cells and tumor microenvironment (TME) is well described in breast cancer, little is known about how the interplay of immune state and cancer metabolism evolves...
3.
Fleischer T, Haugen M, Ankill J, Silwal-Pandit L, Borresen-Dale A, Hedenfalk I, et al.
Mol Oncol
. 2024 Apr;
18(8):2042-2059.
PMID: 38671580
Treatment with the anti-angiogenic drug bevacizumab in addition to chemotherapy has shown efficacy for breast cancer in some clinical trials, but better biomarkers are needed to optimally select patients for...
4.
Zhu Y, Zerdes I, Matikas A, Cruz I, Bergqvist M, Elinder E, et al.
Breast Cancer Res Treat
. 2024 Jan;
204(2):299-308.
PMID: 38175448
Background: Thymidine kinase 1 (TK1) plays a pivotal role in DNA synthesis and cellular proliferation. TK1 has been studied as a prognostic marker and as an early indicator of treatment...
5.
Tsiknakis N, Tzoras E, Zerdes I, Manikis G, Acs B, Hartman J, et al.
Annu Int Conf IEEE Eng Med Biol Soc
. 2023 Dec;
2023:1-4.
PMID: 38083519
Digital histopathology image analysis of tumor tissue sections has seen great research interest for automating standard diagnostic tasks, but also for developing novel prognostic biomarkers. However, research has mainly been...
6.
Nordenskjold A, Fohlin H, Rosell J, Bengtsson N, Fornander T, Hatschek T, et al.
Breast
. 2023 Jul;
71:63-68.
PMID: 37517154
Background: Tamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated. Material And Methods: We studied 30 years...
7.
Briem O, Kallberg E, Kimbung S, Veerla S, Stenstrom J, Hatschek T, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831605
The presence of CD169 macrophages in the draining lymph nodes of cancer patients is, for unknown reasons, associated with a beneficial prognosis. We here investigated the prognostic impact of tumor-infiltrating...
8.
Matikas A, Johansson H, Gryback P, Bjohle J, Acs B, Boyaci C, et al.
Clin Cancer Res
. 2022 Nov;
29(3):532-540.
PMID: 36449695
Purpose: PREDIX HER2 is a randomized Phase II trial that compared neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP) with trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Rates of pathologic complete response...
9.
Loibl S, Huang C, Mano M, Mamounas E, Geyer Jr C, Untch M, et al.
NPJ Breast Cancer
. 2022 Sep;
8(1):106.
PMID: 36117201
Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients....
10.
Zerdes I, Karafousia V, Mezheyeuski A, Stogiannitsi M, Kuiper R, Moreno Ruiz P, et al.
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572882
We aimed to assess if the discrepant prognostic information between Programmed Death Ligand 1 (PD-L1) protein versus mRNA expression in early breast cancer (BC) could be attributed to heterogeneity in...